Obesity drug developer BioAge seeks up to $587 mln valuation in US IPO
WEB1 day ago · The proposed IPO comes months after BioAge raised $170 million in a funding round led by life sciences investment firm Sofinnova Investments. ... the news and media division of Thomson Reuters, is ...
Obesity drug developer BioAge seeks up to $587 million valuation in US IPO
WEB8 hours ago · The proposed IPO comes months after BioAge raised $170 million in a funding round led by life sciences investment firm Sofinnova Investments. Sofinnova Venture Partners currently has a 7.3% ...
BioAge Labs Files for IPO to Be Led by Goldman, Morgan Stanley
WEBSep 3, 2024 · BioAge Labs Inc., a clinical-stage biotechnology company developing therapies for obesity and metabolic disease, has filed for an initial public offering.
Weight loss drug developer BioAge seeks up to $602M valuation in U.S. IPO
WEBObesity drug developer BioAge Labs (BIOA) has filed regulatory filings as part of its U.S. IPO. It seeks to offer 7.5M shares at a price range of $17 to $19, implying a valuation of up to $602M at ...
Eli Lilly partner BioAge files for US IPO | Reuters
WEBSept 3 (Reuters) - BioAge Labs, an obesity therapy-focused startup that has also collaborated with Eli Lilly (LLY.N), filed for an initial public offering in the United States on Tuesday as it...
Obesity Drugmaker BioAge Seeks $158 Million in IPO, Placement
WEB1 day ago · September 18, 2024 at 4:53 PM EDT. Save. BioAge Labs Inc., a clinical-stage biotechnology company developing therapies for obesity and metabolic disease, is seeking to raise as much as $157.5 ...
Obesity drug developer BioAge sets IPO terms (Pending:BIOA)
WEB9 hours ago · Obesity drug developer BioAge Labs has filed regulatory filings as part of its U.S. IPO. It seeks to offer 7.5M shares at a price range of $17 to $19, implying a valuation of up to $602M at the ...
Eli Lilly partner BioAge files for US IPO - MSN
WEB(Reuters) - BioAge Labs, a biotech startup collaborating with Eli Lilly for its obesity therapy, said on Tuesday it had filed for an initial public offering in the United States. The move comes...
Obesity drug developer BioAge seeks up to $587 mln valuation in US IPO
WEB10 hours ago · Sept 18 (Reuters) – Obesity-focused biotech BioAge Labs said on Wednesday it was seeking a valuation of as much as $587 million in its initial public offering in the United States, according to a regulatory filing. Healthcare firms have done comparatively well in an otherwise subdued U.S. IPO …
Obesity drugmaker BioAge targets $158 million in IPO
WEB1 day ago · Obesity drugmaker BioAge targets $158 million in IPO BY David Morris and Bloomberg The company is offering 7.5 million shares for $17 to $19 apiece, according to a filing Wednesday.